Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

ABSTRACT: A gene expression profiling study was conducted in which skin biopsy samples were collected for RNA extraction and hybridization to microarrays from patients with moderate-to-severe psoriasis who participated in the phase 1, guselkumab first-in-human randomized, double-blind, placebo-controlled trial. At week 12, significant reductions in psoriasis gene expression were observed in guselkumab-treated patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE51440 | GEO | 2014/05/14

SECONDARY ACCESSION(S): PRJNA223228

REPOSITORIES: GEO